Lead Product(s) : Alteplase
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Boehringer Ingelheim Focus Covid-19 Therapy Research on Development of Alteplase
Details : It evaluated efficacy and safety of two different dosing regimens of intravenous alteplase given for up to 5 days on top of best available medical management (standard of care (SOC)), compared with SOC alone.
Product Name : Undisclosed
Product Type : Enzyme
Upfront Cash : Inapplicable
July 26, 2021
Lead Product(s) : Alteplase
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II/ Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : DZIF-10c
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I/ Phase II
Sponsor : Cologne University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
New SARS-CoV-2 Neutralizing Antibody enters Clinical Phase
Details : Phase 1/2a clinical trials will evaluate the safety, pharmacokinetics, and antiviral activity of BI 767551 administered by intravenous infusion and by inhalation. The first patients have already been enrolled.
Product Name : BI 767551
Product Type : Antibody
Upfront Cash : Inapplicable
December 18, 2020
Lead Product(s) : DZIF-10c
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I/ Phase II
Sponsor : Cologne University Hospital
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : BI 764198
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The aim of therapy with BI 764198 is to reduce the need for ventilator support, to improve patient recovery rate & ultimately to save lives. This may alleviate the damage to lung & decrease the severity of acute respiratory complications in patients hosp...
Product Name : BI 764198
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 28, 2020
Lead Product(s) : BI 764198
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
